UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
- --------------------------------------------------------------------------------
SCHEDULE 13G
Amendment No. 1
Under the Securities Exchange Act of 1934
ISIS PHARMACEUTICALS, INC.
(Name of Issuer)
Common Stock, $0.001 Par Value
(Title of Class of Securities)
4643300109
(CUSIP Number)
Wayne P. Merkelson, Esq.
Novartis Corporation
608 Fifth Ave
New York, NY 10020
Telephone: (212) 830-2432
(Name, Address and Telephone Number of
Person Authorized to Receive Notices and
Communications)
Copy to:
Spencer D. Klein, Esq.
Shearman & Sterling
599 Lexington Avenue
New York, New York 10022
Telephone: (212) 848-4000
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
- --------------------------------------------------------------------------------
CUSIP No. 4643300109
(1) Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
Novartis AG
---------------------------------------------------------------
---------------------------------------------------------------
(2) Check the Appropriate Box if a Member of Group (See Instructions)
[ ] (a)
--------------------------------------------------------------
[ ] (b)
--------------------------------------------------------------
(3) SEC Use Only
----------------------------------------------------------
-----------------------------------------------------------------------
(4) Citizenship or Place of Organization Switzerland
---------------------------------
Number of (5) Sole Voting Power 0
Shares ---------------------------
Beneficially
Owned by --------------------------------------------
Each (6) Shared Voting Power 1,819,000
Reporting -------------------------
Person
With --------------------------------------------
(7) Sole Dispositive Power 0
----------------------
--------------------------------------------
(8) Shared Dispositive Power 1,819,000
--------------------
(9) Aggregate Amount Beneficially Owned by Each Reporting Person
1,819,000
--------------------------------------------------------------
(10) Check if the Aggregate Amount in Row (9) Excludes Certain
Shares (See Instructions)
--------------------------------------------------------------
--------------------------------------------------------------
(11) Percent of Class Represented by Amount in Row (9)
4.52%
--------------------------------------------------------------
(12) Type of Reporting Person (See Instructions) CO
-------------------
CUSIP No. 4643300109
(1) Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
Novartis Pharma AG
---------------------------------------------------------------
---------------------------------------------------------------
(2) Check the Appropriate Box if a Member of Group (See Instructions)
[ ] (a)
--------------------------------------------------------------
[ ] (b)
--------------------------------------------------------------
(3) SEC Use Only
----------------------------------------------------------
-----------------------------------------------------------------------
(4) Citizenship or Place of Organization Switzerland
---------------------------------
Number of (5) Sole Voting Power 0
Shares ---------------------------
Beneficially
Owned by --------------------------------------------
Each (6) Shared Voting Power 1,819,000
Reporting -------------------------
Person
With --------------------------------------------
(7) Sole Dispositive Power 0
----------------------
--------------------------------------------
(8) Shared Dispositive Power 1,819,000
--------------------
(9) Aggregate Amount Beneficially Owned by Each Reporting Person
1,819,000
--------------------------------------------------------------
(10) Check if the Aggregate Amount in Row (9) Excludes Certain
Shares (See Instructions)
--------------------------------------------------------------
--------------------------------------------------------------
(11) Percent of Class Represented by Amount in Row (9)
4.52%
--------------------------------------------------------------
(12) Type of Reporting Person (See Instructions) CO
-------------------
CUSIP No. 4643300109
(1) Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
Novartis Pharmaceuticals Corporation
---------------------------------------------------------------
---------------------------------------------------------------
(2) Check the Appropriate Box if a Member of Group (See Instructions)
[ ] (a)
--------------------------------------------------------------
[ ] (b)
--------------------------------------------------------------
(3) SEC Use Only
----------------------------------------------------------
-----------------------------------------------------------------------
(4) Citizenship or Place of Organization Switzerland
---------------------------------
Number of (5) Sole Voting Power 0
Shares ---------------------------
Beneficially
Owned by --------------------------------------------
Each (6) Shared Voting Power 0
Reporting -------------------------
Person
With --------------------------------------------
(7) Sole Dispositive Power 0
----------------------
--------------------------------------------
(8) Shared Dispositive Power 0
--------------------
(9) Aggregate Amount Beneficially Owned by Each Reporting Person
0
--------------------------------------------------------------
(10) Check if the Aggregate Amount in Row (9) Excludes Certain
Shares (See Instructions)
--------------------------------------------------------------
--------------------------------------------------------------
(11) Percent of Class Represented by Amount in Row (9)
0%
--------------------------------------------------------------
(12) Type of Reporting Person (See Instructions) CO
-------------------
CUSIP No. 4643300109
(1) Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
Genetic Therapy, Inc.
---------------------------------------------------------------
---------------------------------------------------------------
(2) Check the Appropriate Box if a Member of Group (See Instructions)
[ ] (a)
--------------------------------------------------------------
[ ] (b)
--------------------------------------------------------------
(3) SEC Use Only
----------------------------------------------------------
-----------------------------------------------------------------------
(4) Citizenship or Place of Organization Delaware
---------------------------------
Number of (5) Sole Voting Power 0
Shares ---------------------------
Beneficially
Owned by --------------------------------------------
Each (6) Shared Voting Power 0
Reporting -------------------------
Person
With --------------------------------------------
(7) Sole Dispositive Power 0
----------------------
--------------------------------------------
(8) Shared Dispositive Power 0
--------------------
(9) Aggregate Amount Beneficially Owned by Each Reporting Person
0
--------------------------------------------------------------
(10) Check if the Aggregate Amount in Row (9) Excludes Certain
Shares (See Instructions)
--------------------------------------------------------------
--------------------------------------------------------------
(11) Percent of Class Represented by Amount in Row (9)
0%
--------------------------------------------------------------
(12) Type of Reporting Person (See Instructions) CO
-------------------
Item 1. Issuer
This Amendment to Schedule 13G (the "Amendment") amends the Statement
on Schedule 13G filed on February 13, 1999 by Novartis AG with respect
to shares of Common Stock of the Issuer listed below.
(a) Isis Pharmaceuticals, Inc.
(b) 2292 Faraday Avenue
Carlsbad, California 92008
Item 2. Person Filing
(a) Name of Person Filing: Novartis AG ("Novartis"), Novartis Pharma
AG, Novartis Pharmaceuticals Corporation and Genetic Therapy, Inc.
(together, the "Filers")
(b) Address of Principal Office:
(i) The principal offices of Novartis are located at
Lichtstrasse 35, CH-4002, Basel, Switzerland.
(ii) The principal offices of Novartis Pharma AG are located at
Lichtstrasse 35, CH-4002, Basel, Switzerland.
(iii) The principal offices of Novartis Pharmaceuticals
Corporation are located at 59 Route 10, East Hanover, New
Jersey 07936.
(iv) The principal offices of Genetic Therapy, Inc. are located
at 938 Clopper Road, Gaithersburg, Maryland 20878.
(c) Citizenship: Novartis and Novartis Pharma AG are Swiss
corporations. Novartis Pharmaceuticals Corporation and Genetic
Therapy, Inc. are Delaware corporations.
(d) Title of Class of Securities: Common Stock, $0.001 par value.
(e) CUSIP Number: 464300109
Item 3. This statement is filed pursuant toss.240.13d-1(c).
Item 4. Ownership
(a) Amount Beneficially Owned: Novartis Pharma AG beneficially owns
1,819,000 shares of Common Stock.
(b) Percent of Class: 4.52%
(c) Number of shares as to which each person has:
(i) Sole Voting Power: -0-
(ii) Shared Voting Power: 1,819,000
(iii) Sole Dispositive Power: -0-
(iv) Shared Dispositive Power: 1,819,000
Item 5. Ownership of Five Percent or Less of a Class
As of the date of the filing of the Amendment, the Filers cease to
beneficially own more than five percent of the Common Stock.
Item 6. Ownership of More than Five Percent on Behalf of Another Person
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company
Not applicable.
Item 8. Identification and Classification of Members of the Group
Not Applicable.
Item 9. Notice of Dissolution of Group
Not Applicable.
Item 10. Certification if Statement Filed Pursuant to Rule 13d-1(c)
(a) Not applicable.
(b) By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a
participant in any transaction having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
Date: August 30, 2001
NOVARTIS AG
By: /s/ George Miller
-------------------------
Name: George Miller, Esq.
By: /s/ Dr. Urs Baerlocher
-------------------------
Name: Dr. Urs Baerlocher
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
Date: August 30, 2001
NOVARTIS PHARMA AG
By: /s/ Joseph E. Mamie
-----------------------
Name: Joseph E. Mamie
By: /s/ Dr. Herbert Gut
-----------------------
Name: Dr. Herbert Gut
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
Date: August 30, 2001
NOVARTIS PHARMACEUTICALS
CORPORATION
By: /s/ Gary Rosenthal
----------------------
Name: Gary Rosenthal
Title: Vice President
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
Date: August 30, 2001
GENETIC THERAPY, INC.
By: /s/ David Langham
------------------------
Name: David Langham
Title: Vice President